Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Oncology in Clinical Practice
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2020 Professor Krzysztof Krzemieniecki Award

open access

Vol 14, No 6 (2018)
Review paper
Published online: 2019-03-15
View PDF Download PDF file
Get Citation

Liposarcoma — spectrum of disease

Hanna Koseła-Paterczyk, Michał Wągrodzki
DOI: 10.5603/OCP.2018.0047
·
Oncol Clin Pract 2018;14(6):341-347.

open access

Vol 14, No 6 (2018)
REVIEW ARTICLES
Published online: 2019-03-15

Abstract

Liposarcomas are the most common soft tissue sarcomas in adults. Diagnosis and treatment of liposarcoma should always be planned and conducted in centres experienced in the treatment of these heterogeneous malignancies with different prognosis and sensitivity to the treatment used. In the following paper, we present a summary of current knowledge about liposarcomas considering the differences between subtypes and new directions in treatment.

Abstract

Liposarcomas are the most common soft tissue sarcomas in adults. Diagnosis and treatment of liposarcoma should always be planned and conducted in centres experienced in the treatment of these heterogeneous malignancies with different prognosis and sensitivity to the treatment used. In the following paper, we present a summary of current knowledge about liposarcomas considering the differences between subtypes and new directions in treatment.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

soft tissue sarcoma; liposarcoma; multimodality therapy

About this article
Title

Liposarcoma — spectrum of disease

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 6 (2018)

Article type

Review paper

Pages

341-347

Published online

2019-03-15

DOI

10.5603/OCP.2018.0047

Bibliographic record

Oncol Clin Pract 2018;14(6):341-347.

Keywords

soft tissue sarcoma
liposarcoma
multimodality therapy

Authors

Hanna Koseła-Paterczyk
Michał Wągrodzki

References (48)
  1. Hoang NT, Acevedo LA, Mann MJ, et al. A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Manag Res. 2018; 10: 1089–1114.
    CrossRefPubMed
  2. Fletcher CDM. The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification. Histopathology. 2014; 64(1): 2–11.
    CrossRefPubMed
  3. Dalal KM, Kattan MW, Antonescu CR, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006; 244(3): 381–391.
    CrossRefPubMed
  4. Lucas DR, Nascimento AG, Sanjay BK, et al. Well-differentiated liposarcoma. The Mayo Clinic experience with 58 cases. Am J Clin Pathol. 1994; 102(5): 677–683.
    PubMed
  5. London J, Kim EE, Wallace S, et al. MR imaging of liposarcomas: correlation of MR features and histology. J Comput Assist Tomogr. 1989; 13(5): 832–835.
    PubMed
  6. Creytens D, van Gorp J, Savola S, et al. Atypical spindle cell lipoma: a clinicopathologic, immunohistochemical, and molecular study emphasizing its relationship to classical spindle cell lipoma. Virchows Arch. 2014; 465(1): 97–108.
    CrossRefPubMed
  7. McCarthy AJ, Chetty R. Tumours composed of fat are no longer a simple diagnosis: an overview of fatty tumours with a spindle cell component. J Clin Pathol. 2018; 71(6): 483–492.
    CrossRefPubMed
  8. Sato D, Suga H, Takushima A. Liposarcoma Preoperatively Diagnosed as Lipoma: 10-Year Experience at a Single Institution. Dermatol Surg. 2018; 44(8): 1065–1069.
    CrossRefPubMed
  9. Weaver J, Goldblum JR, Turner S, et al. Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. Mod Pathol. 2009; 22(1): 66–70.
    CrossRefPubMed
  10. Mariño-Enriquez A, Nascimento AF, Ligon AH, et al. Atypical Spindle Cell Lipomatous Tumor: Clinicopathologic Characterization of 232 Cases Demonstrating a Morphologic Spectrum. Am J Surg Pathol. 2017; 41(2): 234–244.
    CrossRefPubMed
  11. Mentzel T, Palmedo G, Kuhnen C. Well-differentiated spindle cell liposarcoma ('atypical spindle cell lipomatous tumor') does not belong to the spectrum of atypical lipomatous tumor but has a close relationship to spindle cell lipoma: clinicopathologic, immunohistochemical, and molecular analysis of six cases. Mod Pathol. 2010; 23(5): 729–736.
    CrossRefPubMed
  12. Patel RB, Li T, Liao Z, et al. Recent translational research into targeted therapy for liposarcoma. Stem Cell Investig. 2017; 4: 21.
    CrossRefPubMed
  13. Arrigoni G, Doglioni C. Atypical lipomatous tumor: molecular characterization. Curr Opin Oncol. 2004; 16(4): 355–358.
    PubMed
  14. Thway K, Flora R, Shah C, et al. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol. 2012; 36(3): 462–469.
    CrossRefPubMed
  15. Evans HL, Soule EH, Winkelmann RK. Atypical lipoma, atypical intramuscular lipoma, and well differentiated retroperitoneal liposarcoma: a reappraisal of 30 cases formerly classified as well differentiated liposarcoma. Cancer. 1979; 43(2): 574–584.
    PubMed
  16. Kindblom LG, Angervall L, Fassina AS. Atypical lipoma. Acta Pathol Microbiol Immunol Scand A. 1982; 90(1): 27–36.
    PubMed
  17. Evans HL. Liposarcoma: a study of 55 cases with a reassessment of its classification. Am J Surg Pathol. 1979; 3(6): 507–523.
    PubMed
  18. Saeed-Chesterman D, Thway K. Homologous Lipoblastic Differentiation in Dedifferentiated Liposarcoma. Int J Surg Pathol. 2016; 24(3): 237–239.
    CrossRefPubMed
  19. Evans HL. Atypical lipomatous tumor, its variants, and its combined forms: a study of 61 cases, with a minimum follow-up of 10 years. Am J Surg Pathol. 2007; 31(1): 1–14.
    CrossRefPubMed
  20. Mussi C, Collini P, Miceli R, et al. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution. Cancer. 2008; 113(7): 1657–1665.
    CrossRefPubMed
  21. Gronchi A, Collini P, Miceli R, et al. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. Am J Surg Pathol. 2015; 39(3): 383–393.
    CrossRefPubMed
  22. Dei Tos AP. Liposarcomas: diagnostic pitfalls and new insights. Histopathology. 2014; 64(1): 38–52.
    CrossRefPubMed
  23. Creytens D, Van Gorp J, Speel EJ, et al. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis. Anticancer Res. 2015; 35(4): 1835–1842.
    PubMed
  24. Orvieto E, Furlanetto A, Laurino L, et al. Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia. Semin Diagn Pathol. 2001; 18(4): 267–273.
    PubMed
  25. Estourgie SH, Nielsen GP, Ott MJ. Metastatic patterns of extremity myxoid liposarcoma and their outcome. J Surg Oncol. 2002; 80(2): 89–93.
    CrossRefPubMed
  26. Kilpatrick SE, Doyon J, Choong PF, et al. The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer. 1996; 77(8): 1450–1458, doi: 10.1002/(SICI)1097-0142(19960415)77:8<1450::AID-CNCR5>3.0.CO;2-G.
    PubMed
  27. Smith TA, Easley KA, Goldblum JR. Myxoid/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma. Am J Surg Pathol. 1996; 20(2): 171–180.
    PubMed
  28. Wang L, Ren W, Zhou X, et al. Pleomorphic liposarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic study of 32 additional cases. Pathol Int. 2013; 63(11): 523–531.
    CrossRefPubMed
  29. Ghadimi MP, Liu P, Peng T, et al. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer. 2011; 117(23): 5359–5369.
    CrossRefPubMed
  30. Miettinen M, Enzinger FM. Epithelioid variant of pleomorphic liposarcoma: a study of 12 cases of a distinctive variant of high-grade liposarcoma. Mod Pathol. 1999; 12(7): 722–728.
    PubMed
  31. Huang HY, Antonescu CR. Epithelioid variant of pleomorphic liposarcoma: a comparative immunohistochemical and ultrastructural analysis of six cases with emphasis on overlapping features with epithelial malignancies. Ultrastruct Pathol. 2002; 26(5): 299–308.
    CrossRefPubMed
  32. Val-Bernal JF, González-Vela MC, Cuevas J. Primary purely intradermal pleomorphic liposarcoma. J Cutan Pathol. 2003; 30(8): 516–520.
    PubMed
  33. Wang L, Luo R, Xiong Z, et al. Pleomorphic liposarcoma: An analysis of 6 case reports and literature review. Medicine (Baltimore). 2018; 97(8): e9986.
    CrossRefPubMed
  34. Mariño-Enríquez A, Hornick JL, Dal Cin P, et al. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration. Cancer Cytopathol. 2014; 122(2): 128–137.
    CrossRefPubMed
  35. Crago AM, Dickson MA. Liposarcoma: Multimodality Management and Future Targeted Therapies. Surg Oncol Clin N Am. 2016; 25(4): 761–773.
    CrossRefPubMed
  36. Rutkowski P, Ługowska I. (red.). Mięsaki tkanek miękkich u dorosłych. Onkol Prakt Klin Edu 2017;3(5):203-225.
  37. Crago AM, Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol. 2011; 23(4): 373–378.
    CrossRefPubMed
  38. Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009; 27(1): 24–30.
    CrossRefPubMed
  39. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017; 18(6): 812–822.
    CrossRefPubMed
  40. Casali Pg, Abecassis N, Aro Ht, Et Al. Soft Tissue And Visceral Sarcomas: Esmo-Euracan Clinical Practice Guidelines For Diagnosis, Treatment And Follow-Up. Ann Oncol. 2018;29(Supplement_4):Iv268-Iv269.
  41. Chung PWM, Deheshi BM, Ferguson PC, et al. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas. Cancer. 2009; 115(14): 3254–3261.
    CrossRefPubMed
  42. Pawlik T, Pisters P, Mikula L, et al. Long-Term Results of Two Prospective Trials of Preoperative External Beam Radiotherapy for Localized Intermediate- or High-Grade Retroperitoneal Soft Tissue Sarcoma. Annals of Surgical Oncology. 2006; 13(4): 508–517.
    CrossRef
  43. Jones RL, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005; 41(18): 2853–2860.
    CrossRefPubMed
  44. Patel SR, Burgess MA, Plager C, et al. Myxoid liposarcoma. Experience with chemotherapy. Cancer. 1994; 74(4): 1265–1269.
    PubMed
  45. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009; 27(25): 4188–4196.
    CrossRefPubMed
  46. Jones RL, Demetri GD, Schuetze SM, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016; 34(8): 786–793.
    CrossRefPubMed
  47. Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol. 2009; 20(8): 1439–1444.
    CrossRefPubMed
  48. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007; 8(7): 595–602.
    CrossRefPubMed

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl